Our Leadership

We are guided by world-class scientists and business leaders whose drive and passion to innovate is matched only by their commitment to deliver first-in-class and best-in-class medicines to the patients who need them.

Image
Brett P. Monia, Ph.D.
Brett P. Monia, Ph.D.
Chief Executive Officer

Dr. Monia is the chief executive officer, a member of the board of directors and a founding scientist of Ionis Pharmaceuticals. His contributions at Ionis include research into the medicinal chemistry and mechanisms of action of RNA-targeting modalities to treat human diseases, most notably antisense-based therapeutic strategies. Dr. Monia has extensive experience across a range of therapeutic areas, including oncology, metabolic disease, inflammation, neurological disease and cardiovascular disease, which have resulted in a broad range of successful clinical achievements and in marketing approvals for new medicines.

 

Dr. Monia has published more than 200 primary research manuscripts, reviews and book chapters, and is an inventor on more than 100 issued patents. He serves as a senior editor for the journal Nucleic Acid Therapeutics. He is on the board of directors of Cognition Therapeutics and the board of directors of Flamingo Therapeutics. He has also served as president of the Oligonucleotide Therapeutics Society (OTS). Dr. Monia is also an adjunct professor of biology at San Diego State University where he lectures at the graduate level on pharmacology.

 

Dr. Monia received his Ph.D. in Pharmacology at the University of Pennsylvania and B.S. degrees in Molecular Biology and Analytical Chemistry at Stockton State College in Pomona, New Jersey.

Image
Elizabeth L. Hougen
Elizabeth L. Hougen
Executive Vice President, <br> Chief Financial Officer

Ms. Hougen is our executive vice president of Finance and chief financial officer. As a member of our executive leadership team, Ms. Hougen contributes to the execution of our strategy, including ensuring we are well positioned to be a global, multi-product sustainably profitable company. Ionis’ finance, accounting, tax, treasury, information technology, procurement and investor relations functions report to her. Ms. Hougen joined Ionis in May 2000 as vice president, finance, and became chief accounting officer in January 2007 and chief financial officer in January 2013.

 

Ms. Hougen has an extensive finance and business background having held positions of increasing responsibility in numerous public companies, primarily in the life sciences industry, over her more than 25-year career. Prior to joining Ionis, Ms. Hougen was chief financial officer for Molecular Biosystems, Inc., a public biotechnology company.

 

In recognition of her important contributions to the financial success of Ionis, in 2018 Ms. Hougen was named a CFO of the Year by the San Diego Business Journal. Ms. Hougen received her M.B.A. from the University of San Diego and her B.A. from Franklin and Marshall College.

Image
C. Frank Bennett, Ph.D.
C. Frank Bennett, Ph.D.
Executive Vice President, <br>Chief Scientific Officer

Dr. Bennett is the executive vice president and chief scientific officer at Ionis Pharmaceuticals and one of the founding members of the company. He is responsible for continuing to advance Ionis’ technology and expanding the company’s drug discovery platform. Dr. Bennett is also the franchise leader for gene-editing programs at Ionis. He has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory, neurodegenerative diseases and cancer, oligonucleotide delivery, pharmacokinetics and medicinal chemistry.

 

Dr. Bennett has been recognized for his research with numerous awards. He is a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research, the 2021 Gabbay Award and the 2019 Breakthrough Prize in Life Sciences for his contributions to the discovery and development of SPINRAZA® (nusinersen), and the inaugural Healy Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS). Dr. Bennett also received the 2018 Hereditary Disease Foundation's (HDF) Leslie Gehry Brenner Prize for Innovation in Science for his leadership and continued commitment to developing antisense therapies for Huntington's disease (HD).

 

Dr. Bennett has published more than 230 papers in the field of antisense research and development, and he is an inventor on more than 175 issued patents.

 

Prior to joining Ionis, Dr. Bennett was associate senior investigator in the Department of Molecular Pharmacology at SmithKline and French Laboratories (currently, GlaxoSmithKline).

 

He received his Ph.D. in Pharmacology from Baylor College of Medicine, Houston, Texas and his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico. He performed his postdoctoral research in the Department of Molecular Pharmacology at SmithKline and French Laboratories.

 

Dr. Bennett serves on the Advisory Board for the Hereditary Disease Foundation and SAB for the McLaughlin Institute.

Image
Kyle Jenne
Kyle Jenne
Executive Vice President, <br> Chief Global Product Strategy Officer

Mr. Jenne is Ionis’ executive vice president, chief global product strategy officer. He has more than 25 years of biopharmaceutical experience launching and commercializing innovative medicines in the U.S. and globally. He has broad relevant experience in rare, specialty and common diseases across therapeutic areas including cardiovascular, neurology and allergy.

 

Mr. Jenne leads all aspects of commercialization including marketing, sales, commercial operations, market access and patient services. He also oversees Ionis’ portfolio planning, market insights and medical affairs functions.

 

Before rejoining Ionis in 2024, Mr. Jenne previously spent five years in senior commercial leadership roles at Ionis and Akcea, which was fully acquired by Ionis in 2020. During his time at Ionis and Akcea, Mr. Jenne built commercial capabilities in many of Ionis’ key disease areas including transthyretin-mediated amyloidosis and familial chylomicronemia syndrome. Earlier in his career, Mr. Jenne held commercial roles for companies including Schering Plough, King Pharmaceuticals, Acorda Therapeutics and Praecis Pharmaceuticals. Mr. Jenne holds a BS in Marketing from Arizona State University.

Image
Joseph T. Baroldi, M.A., M.B.A., M.S.
Joseph T. Baroldi, M.A., M.B.A., M.S.
Executive Vice President, <br>Chief Business Officer

Mr. Baroldi is our executive vice president and chief business officer. As a member of the executive leadership team, he is responsible for leading and providing strategic guidance for Ionis' business development and alliance management activities.

 

Mr. Baroldi has more than two decades of industry experience. Prior to Ionis, he was chief operating officer at Avidity Biosciences, where he played an integral role in their initial public offering and building their team. Previously, he was vice president, business development at Ionis, where he held several roles of increasing responsibility over 10 years. Before that Mr. Baroldi held positions in strategic planning and scientific research.

 

Mr. Baroldi holds an M.B.A. from the Rady School of Management at the University of California-San Diego. He received his B.S. in Biological Sciences from the University of California-Irvine.

Image
Richard S. Geary, Ph.D.
Richard S. Geary, Ph.D.
Executive Vice President, <br> Chief Development Officer

Dr. Geary is the executive vice president and chief development officer at Ionis Pharmaceuticals. He is responsible for preclinical development, clinical development and clinical-stage manufacturing for Ionis’ antisense medicines. Since joining Ionis in 1995, Dr. Geary has been involved in discovery and development including the regulatory submission of more than 40 investigational new drug applications to U.S. and other regulatory agencies. In his position as head of development, Dr. Geary has led four successful antisense medicine late stage development programs through approvals in multiple jurisdictions.

 

During his tenure at Ionis, he has authored or co-authored 14 book chapters and more than 80 peer-reviewed manuscripts, which form a body of work that fully characterize the pharmacokinetics and metabolism of antisense medicines and the relationship of drug concentrations to activity and safety. Dr. Geary also serves on the Oligonucleotide Therapeutics Society (OTS) Board of Directors and co-leads the publication committee for Nucleic Acid Therapeutics.

 

Prior to joining Ionis, Dr. Geary was senior research scientist and group leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute. Dr. Geary received his Ph.D. in Biopharmaceutics from the University of Texas, College of Pharmacy, Austin, Texas and his B.S. in Biology from Texas A&M University, College Station, Texas.

Image
Patrick R. O’Neil, Esq.
Patrick R. O’Neil, Esq.
Chief Legal Officer and General Counsel

Mr. O’Neil is the Chief Legal Officer and General Counsel of Ionis Pharmaceuticals. He is responsible for managing the legal, patent and GCP QA/QC departments. Mr. O’Neil also serves as Ionis’ corporate secretary. Mr. O’Neil joined Ionis in October 2001.

 

Prior to joining Ionis, Mr. O’Neil was an associate at Cooley LLP.

 

Mr. O’Neil received his BS in Business Administration, Finance Concentration from the University of San Francisco and his J.D. at UC Davis School of Law.

Image
Eric E. Swayze, Ph.D.
Eric E. Swayze, Ph.D.
Executive Vice President, <br>Research

Dr. Swayze is executive vice president of Research at Ionis Pharmaceuticals. He is responsible for leading preclinical antisense drug discovery and antisense technology research.

 

Previously, Dr. Swayze was vice president of Chemistry and Neuroscience Drug Discovery at Ionis, overseeing the advancement of multiple programs to clinical development. He joined Ionis in 1994 and has contributed to key technology advancements, including Ionis' Generation 2.5 chemistry and LIgand-Conjugated Antisense (LICA) technology.

 

He is an author on more than 150 scientific manuscripts, several reviews and book chapters, and is an inventor of more than 140 issued US patents. He received his Ph.D. in Organic Chemistry at the University of Michigan under the guidance of Professor Leroy B. Townsend.

Image
Eugene Schneider, M.D.
Eugene Schneider, M.D.
Executive Vice President, <br>Chief Clinical Development and Operations Officer

Dr. Schneider is executive vice president and chief clinical development and operations officer of Ionis Pharmaceuticals. As a member of our executive leadership team, Dr. Schneider oversees all stages of clinical development of Ionis’ antisense medicines across the company’s therapeutic franchises. Dr. Schneider joined Ionis in December 2013 as executive director, clinical development and became vice president, clinical development, severe and rare diseases in April 2015, senior vice president, head of clinical development in August 2018 and executive vice president, chief clinical development officer in January 2021.

 

Dr. Schneider has two decades of experience in clinical development primarily in the rare diseases space. Prior to joining Ionis, Dr. Schneider was senior medical director at both Synageva BioPharma and Biovail Technologies Ltd.

 

Dr. Schneider received his medical degree from University of Medicine and Dentistry of New Jersey and completed his training in Pediatric and Adolescent Medicine at Robert Wood Johnson University Hospital in New Brunswick, New Jersey.

Image
Brian Birchler
Brian Birchler
Executive Vice President, <br>Corporate and Development Operations

Mr. Birchler is Ionis’ executive vice president, corporate and development operations. In this role, he provides executive leadership for several functions, including clinical operations and data management, global project and portfolio management, biometrics and clinical supplies. He also provides management support for development and research budgets and product launch excellence. Mr. Birchler is a member of Ionis' executive leadership team.

 

Mr. Birchler has over 30 years of experience in the biopharmaceutical and medical device industries and broad knowledge of the drug development process from concept through launch. Since joining Ionis in 1995 he has held positions of increasing responsibility in development, clinical research and development chemistry. Before Ionis, he held positions at CIBA Vision Corp. and Burroughs Wellcome Pharmaceuticals. Mr. Birchler has a bachelor’s degree in industrial technology from the University of Wisconsin-Stout.

Image
Shannon Devers, MBA
Shannon L. Devers
Executive Vice President,<br/> Chief Human Resources Officer

Ms. Devers is our executive vice president and chief human resources officer. Ms. Devers joined Ionis in February 2001 as a senior human resources manager and as a director assumed full responsibility for human resources and campus operations in 2006. In 2020, as Senior Vice President, Ms. Devers expanded her scope to include our facilities organization.

 

Ms. Devers has been an integral part of Ionis for over two decades, demonstrating strong leadership and strategic insight in the field of Human Resources. Before joining Ionis, Ms. Devers gained valuable HR experience in roles at Target Corporation, Nike, Inc., and Taco Bell Corporation. 

 

Ms. Devers has played a critical role in shaping Ionis’ company culture, driving organizational change, fostering innovation, and focusing on environmental sustainability. She has provided strategic guidance to align HR and Facilities initiatives with the organization’s overall goals and objectives. She has been instrumental in shaping and reinforcing the company's culture and core principles, facilitating internal training programs, and spearheading initiatives to enhance employee integration, engagement, and retention. Her strategic vision and operational expertise have contributed to Ionis’ growth and success.

 

Ms. Devers holds a Master of Business Administration in Human Resource Management and Marketing from the University of Florida and a Bachelor of Science in Business Administration, cum laude, with a focus on Marketing from the University of Central Florida.

 

 

Image
Adam Mullick, Ph.D.
Adam Mullick, Ph.D.
VP, Drug Discovery
Image
Alexey S. Revenko, Ph.D.
Alexey S. Revenko, Ph.D.
VP, Pulmonary
Image
Andy Watt
Andy Watt
VP, Lead Identification
Image
Anne V. Smith, Ph.D.
Anne V. Smith, Ph.D.
VP, Clinical Development
Image
Anthony Scozzari
Anthony Scozzari
SVP, Development Chemistry & Manufacturing
Image
Belinda S. Cowling, Ph.D.
Belinda S. Cowling, Ph.D.
VP, Biomarkers Research
Image
Bret A. Coldren, Ph.D.
Bret A. Coldren, Ph.D.
VP, Gene Editing
Image
Bryan J. Tayefeh
Bryan J. Tayefeh
VP, Strategic Alliances & Transactions
Image
Charles Asare, M.D., MPH
Charles Asare, M.D., MPH
VP, Head of Drug Safety
Image
Christopher Kramer, M.A.
Christopher Kramer, M.A.
VP, Portfolio Planning & Market Insights
Image
Claus A. Rentel
Claus A. Rentel
VP, Analytical Chemistry
Image
Cliff Ford, J.D.
Cliff Ford, J.D.
SVP, Intellectual Property
Image
Daniel Capaldi, Ph.D.
Daniel Capaldi, Ph.D.
VP, Analytical & Process Chemistry
Image
Darren Gonzales
Darren Gonzales
SVP & Chief Accounting Officer
Image
Dave Ecker, Ph.D.
Dave Ecker, Ph.D.
VP, Strategic Innovation
Image
Dawn Henson Hannough, DEC. B.Sc., M.B.A.
Dawn Henson Hannough, DEC. B.Sc., M.B.A.
VP, Product Marketing
Image
Eric P. Bastings, M.D.
Eric P. Bastings, M.D.
VP, Development Strategy
Image
Erin Lettow
Erin Lettow
VP, Global Project & Portfolio Management
Image
Erin Morgan
Erin Morgan
VP, Clinical Development
Image
Ewa Karwatowska-Prokopczuk, M.D., Ph.D.
Ewa Karwatowska-Prokopczuk, M.D., Ph.D.
VP, Cardiovascular Medicine
Image
Frank Rigo, Ph.D.
Frank Rigo, Ph.D.
SVP, Functional Genomics
Image
Hala B. Mirza
Hala B. Mirza
SVP, Corporate Affairs & Patient Advocacy
Image
Hayley Soffer
Hayley Soffer
VP, Corporate Communications
Image
Holly Kordasiewicz, Ph.D.
Holly Kordasiewicz, Ph.D.
SVP, Neurology
Image
Jason P. Zwerner, M.A., M.B.A., M.S.
Jason P. Zwerner
VP, Brand Lead Olezarsen
Image
John Su, Ph.D.
John Su, Ph.D.
VP, Biometrics
Image
Jonathan Birchall, MBA
Jonathan Birchall, MBA
SVP & Chief Commercial Officer
Image
Kara Malewicz, MBA
Kara Malewicz, MBA
VP, New Product Commercialization
Image
Kenneth Newman, M.D., MBA
Kenneth Newman, M.D., MBA
SVP, Clinical Development
Image
Kim P. Doan
Kim P. Doan
VP, Clinical Operations
Image
Marci J. Macpherson, M.S.
Marci J. Macpherson, M.S.
VP, Development Quality Assurance
Image
Matt Buck, J.D.
Matt Buck, J.D.
SVP, Regulatory Affairs
Image
Max Moore
Max Moore
VP, Manufacturing/Operations
Image
Melissa M. Yoon, J.D.
Melissa M. Yoon, J.D.
VP, Legal & Deputy General Counsel
Image
Mickael G. Rabilloud, MAI, KEDGE
Mickael G. Rabilloud, MAI, KEDGE
VP, Strategic Sourcing
Image
Rachel M. Carnes
Rachel M. Carnes
SVP, Global Product Strategy
Image
Roger Lane, M.D., MPH
Roger Lane, M.D., MPH
SVP, Clinical Development
Image
Sam Tsimikas, M.D.
Sam Tsimikas, M.D.
SVP, Global Cardiovascular Development
Image
Sanjay Bhanot, M.D., Ph.D.
Sanjay Bhanot, M.D., Ph.D.
SVP, Chief Medical Officer & Cardiometabolic Franchise Leader
Image
Scott Henry, Ph.D.
Scott Henry, Ph.D.
SVP, Preclinical Development
Image
Shay Bujanover, M.D., MBA
Shay Bujanover, M.D., MBA
VP, Medical Affairs
Image
Sheetal K. Patel, Ph.D.
Sheetal K. Patel, Ph.D.
VP, US Market Access and Reimbursement
Image
Shuling Guo, Ph.D.
Shuling Guo, Ph.D.
VP, Drug Discovery
Image
Sujit K. Basu, Ph.D.
Sujit K. Basu, Ph.D.
VP, Head of Pharmaceutical Development
Image
Tae-Won Kim, Ph.D.
Tae-Won Kim, Ph.D.
VP, Toxicology
Image
Tiffany L. Baumann
Tiffany L. Baumann
VP, Regulatory Affairs
Image
Tracy Berns, J.D.
Tracy Berns, J.D.
SVP, Chief Compliance & Quality Assurance Officer
Image
Wade Walke, Ph.D.
Wade Walke, Ph.D.
SVP, Investor Relations
Image
Wayne Sanders
Wayne Sanders
VP, Facilities
Image
Xiang Gao, Ph.D.
Xiang Gao, Ph.D.
VP, Pharmacokinetics & Clinical Pharmacology
Joseph Loscalzo, MD, PhD
Chairman of the Board, Head of Department of Medicine and Physician-in-Chief, Brigham & Woman’s Hospital, Harvard Medical School
Brett P. Monia, PhD
Chief Executive Officer
Spencer R. Berthelsen, MD
Managing Director, Kelsey-Seybold Clinic, Ret.
Allene M. Diaz
Independent Director, Mersana Therapeutics and Ionis Pharmaceuticals Senior Advisor, Bain Capital Life Sciences
Michael Hayden, CM, OBC, MB, ChB, PhD, FRCP(C), FRSC
Killam Professor at the University of British Columbia and the Director of the Translational Laboratory in Genetic Medicine
Joan E. Herman
President and CEO, Herman and Associates
Joseph Klein, III
Managing Director, Gauss Capital Advisors, LLC
B. Lynne Parshall, Esq.
Senior Strategic Advisor, Ionis
Joseph H. Wender
Senior Consultant, Goldman Sachs & Co.
Michael Yang
Biotech Board Director and Advisor